Hadassah and Neurogenesis announce results from Phase 2 MS Study
A Phase 2 study at Hadassah Hospital Ein Kerem has revealed significant clinical improvements in patients with progressive multiple sclerosis (MS) after being treated with NG-01 stem cells developed by NeuroGenesis, a clinical-stage biopharmaceutical company advancing innovative cell therapies to combat neurodegenerative diseases. The 14-month randomized, double blind, placebo-controlled study, comprised of 48 patients, was led by Prof. […]
